Detalhe da pesquisa
1.
Discovery of novel heat shock protein (Hsp90) inhibitors based on luminespib with potent antitumor activity.
Bioorg Med Chem Lett
; 30(12): 127165, 2020 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32305165
2.
Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist.
Biomed Pharmacother
; 173: 116331, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38428307
3.
Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety.
Mol Cancer Ther
; 22(3): 333-342, 2023 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36808277
4.
Discovery of Novel Dual Adenosine A2A and A1 Receptor Antagonists with 1H-Pyrazolo[3,4-d]pyrimidin-6-amine Core Scaffold as Anti-Parkinson's Disease Agents.
Pharmaceuticals (Basel)
; 15(8)2022 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35893746
5.
6-Alkylsalicylic acid analogues inhibit in vitro ATPase activity of heat shock protein 90.
Arch Pharm Res
; 33(12): 1997-2001, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21191765
6.
New non-quinone geldanamycin analogs from genetically engineered Streptomyces hygroscopicus.
J Antibiot (Tokyo)
; 64(6): 461-3, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21448187